Back to results
US 2020/0231941 A1Published application
Genetically engineered coxsackievirus, and pharmaceutical composition
AssigneesThe University of Tokyo, Shin Nihon Seiyaku Co., Ltd
InventorsYang JIA, Shohei MIYAMOTO, Kenichiro HARA, Atsuhumi IWANAGA, Kenzaburo TANI
Life of this patent
Estimating the term…
Abstract
A gene-modified coxsackievirus that is to be used in oncolytic virotherapy and is improved in safety and/or aggressiveness is provided. A gene-modified coxsackievirus that contains a mutated genome with a coxsackievirus B3 wild-type (CVB3-WT) genome inserted with at least one polynucleotide constituted of a target sequence for at least one of either of miR-34a and miR-34c and is suppressed in proliferation in normal cells is provided.
Claims16
A gene-modified coxsackievirus comprising:
- a mutated genome including a coxsackievirus wild-type (CVB3-WT) genome, the CVB3-WT genome inserted with at least one polynucleotide wherein the polynucleotide includes a target sequence for a normal-cell-specific or tissue-specific microRNA (miRNA),
- wherein proliferation of the gene-modified coxsackievirus is suppressed specifically in normal cells and
- wherein the target sequence for the normal-cell-specific miRNA corresponds to at least one of miR-34a and miR-34c, and
- a position of insertion of the polynucleotide includes at least a position between position 742 and position 743 inside a 5′ UTR region of the CVB3-WT genome.
1 more element
Dependencies are inferred from the claim text.